- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03602820
Long-term Follow-up Study in Subjects Who Received Voretigene Neparvovec-rzyl (AAV2-hRPE65v2)
February 23, 2024 updated by: Spark Therapeutics
A Long-Term Follow-Up Study in Subjects Who Received an Adenovirus-Associated Viral Vector Serotype 2 Containing the Human RPE65 Gene (AAV2-hRPE65v2, Voretigene Neparvovec-rzyl) Administered Via Subretinal Injection
Multi-site, non-randomized, observational study, for up to 15 years after subretinal AAV2-hRPE65v2 administration for each subject.
The study is a non-interventional, follow-up study of subjects who participated in previous AAV2-hRPE65v2 gene therapy clinical trials.
Study Overview
Status
Active, not recruiting
Intervention / Treatment
Detailed Description
This is an observational follow-up study of subjects who participated in previous Phase 1 and Phase 3 clinical trials of AAV2-hRPE65v2 gene therapy (voretigene neparvovec-rzyl) to evaluate long term durability and safety for 15 years after subretinal administration.
Study Type
Observational
Enrollment (Actual)
41
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
Individuals who received the subretinal administration of AAV2-hRPE65v2 (voretigene neparvovec-rzyl) in the Phase 1 or Phase 3 clinical trials
Description
Inclusion Criteria:
1. Subjects who participated in prior subretinal AAV2-hRPE65v2 gene therapy clinical studies
Exclusion Criteria:
- Subjects who will not consent for study.
- Subjects who the investigators believe are not capable of performing study assessments
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mobility testing, Bilateral
Time Frame: 15 years
|
Mobility testing will be videotaped at each study visit at which it is conducted.
Independent reviewers may grade subjects' mobility videos.
Graders will use a defined combination of speed and accuracy to grade each course attempt at a given light intensity.
The course will be re-configured between each attempt, using twelve standardized templates, to reduce the impact of a potential learning effect.
Each subject will be tested, using both eyes, under at least two and sometimes three different (specified) lighting conditions.
The levels of light, selected to span lighting conditions that individuals encounter in daily life, range from a studio with floodlights (400 lux) or a brightly lit office (250 lux) down to a poorly lit sidewalk at night (1 lux).
|
15 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Full-field light sensitivity threshold (FST) testing
Time Frame: 15 years
|
FST testing measures the light sensitivity of the entire visual field by recording the luminance at which a subject reports seeing the dimmest flash.
The test is carried out on subjects with dilated eyes in a dark-adapted state; subjects are seated in front of a Ganzfeld dome in which the light flashes are generated.
The light sensitivity of each eye is measured separately by patching one eye (and then the other).
A sound is generated and the subject presses one button when they see a flash or a second button if they do not see a flash.
Flashes of varying luminance (in a range spanning ~80 dB) are presented in a randomized order with no flashes, except that the series starts with dim flashes.
From this data, an algorithm calculates the minimum luminance (for each eye) at which the subject perceives light.
|
15 years
|
Mobility testing, Monocular
Time Frame: 15 years
|
Mobility testing will be videotaped at each study visit at which it is conducted.
Independent reviewers may grade subjects' mobility videos.
Graders will use a defined combination of speed and accuracy to grade each course attempt at a given light intensity.
The course will be re-configured between each attempt, using twelve standardized templates, to reduce the impact of a potential learning effect.
Each subject will be tested, using the first treated eye, under at least two and sometimes three different (specified) lighting conditions.
The levels of light, selected to span lighting conditions that individuals encounter in daily life, range from a studio with floodlights (400 lux) or a brightly lit office (250 lux) down to a poorly lit sidewalk at night (1 lux).
|
15 years
|
Visual acuity
Time Frame: 15 years
|
Visual acuity measures central vision using the ability to resolve standard optotype images presented as letters corresponding to different visual angles, i.e., image size.
This testing will include age-adapted tests, such as ETDRS testing or HOTV testing (which uses the letters H, O, T, V, which can be identified even by young children and all four of which center around a vertical axis).
The level of central visual resolution is converted to a visual angle score (LogMAR).
Subjects may, in some cases, need to undergo repeated testing sessions, including on successive days, to establish consistent measurements on psychophysical tests, such as visual acuity.
|
15 years
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Visual field testing - Humphrey and/or Goldmann
Time Frame: 15 years
|
Visual field parameters will evaluate alterations in function of different regions of the retina; kinetic fields will be measured with Goldmann perimetry and static fields with Humphrey computerized testing.
|
15 years
|
Visual function questionnaire
Time Frame: 15 years
|
The gene therapy study investigators developed a questionnaire relevant to the deficit experienced by patients with RPE65 gene mutations.
This patient-reported outcome consists of 25 questions pertaining to activities of daily living that are dependent upon vision or have a vision component.
Subjects and/or their parent or guardian will be asked to provide all responses regarding the perceived degree of difficulty of these activities of daily living.
|
15 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Albert Maguire, MD, University of Pennsylvania
- Principal Investigator: Stephen Russell, MD, University of Iowa
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 1, 2015
Primary Completion (Estimated)
March 1, 2030
Study Completion (Estimated)
June 1, 2030
Study Registration Dates
First Submitted
July 18, 2018
First Submitted That Met QC Criteria
July 18, 2018
First Posted (Actual)
July 27, 2018
Study Record Updates
Last Update Posted (Estimated)
February 26, 2024
Last Update Submitted That Met QC Criteria
February 23, 2024
Last Verified
February 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- AAV2-hRPE65v2-LTFU-01
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Inherited Retinal Dystrophy Due to RPE65 Mutations
-
Innostellar Biotherapeutics Co.,LtdActive, not recruitingInherited Retinal Dystrophy Associated With RPE65 MutationsChina
-
Spark Therapeutics, Inc.Children's Hospital of Philadelphia; University of IowaActive, not recruitingLeber Congenital Amaurosis | Inherited Retinal Dystrophy Due to RPE65 MutationsUnited States
-
Frontera TherapeuticsRecruitingBiallelic RPE65 Mutation-associated Retinal DystrophyChina
-
Novartis PharmaceuticalsActive, not recruitingBiallelic RPE65 Mutation-associated Retinal DystrophyJapan
-
Spark TherapeuticsActive, not recruitingConfirmed Biallelic RPE65 Mutation-associated Retinal DystrophyUnited States
-
HuidaGene Therapeutics Co., Ltd.Cholgene Therapeutics, Inc.RecruitingLeber Congenital Amaurosis | Inherited Retinal Diseases Caused by RPE65 MutationsUnited States, China
-
Shahid Beheshti University of Medical SciencesUnknownInherited Retinal Dystrophy Primarily Involving Sensory Retina | Inherited Retinal Dystrophy Primarily Involving Retinal Pigment EpitheliumIran, Islamic Republic of
-
Gangnam Severance HospitalCompletedInherited Retinal Dystrophy Primarily Involving Sensory Retina | Inherited Retinal Dystrophy Primarily Involving Retinal Pigment EpitheliumKorea, Republic of
-
Innostellar Biotherapeutics Co.,LtdRecruitingInherited Retinal DystrophyChina
-
Shanghai General Hospital, Shanghai Jiao Tong University...RecruitingInherited Retinal DystrophiesChina
Clinical Trials on AAV2-hRPE65v2
-
Spark TherapeuticsActive, not recruitingConfirmed Biallelic RPE65 Mutation-associated Retinal DystrophyUnited States
-
Spark Therapeutics, Inc.Children's Hospital of Philadelphia; University of IowaActive, not recruitingLeber Congenital Amaurosis | Inherited Retinal Dystrophy Due to RPE65 MutationsUnited States
-
Spark TherapeuticsActive, not recruitingLeber Congenital AmaurosisUnited States
-
Spark TherapeuticsCompleted
-
MeiraGTx, LLCRecruitingGrade 2 and 3 Late Xerostomia Caused by Radiotherapy for Cancers of the Upper Aerodigestive Tract, Excluding the Parotid GlandsUnited States, Canada
-
Spark TherapeuticsCompletedChoroideremia | CHM (Choroideremia) Gene MutationsUnited States
-
eyeDNA TherapeuticsRecruitingRetinitis PigmentosaFrance
-
Genzyme, a Sanofi CompanyCompletedEye Diseases | Macular Degeneration | Retinal Degeneration | Gene Therapy | Age-Related Maculopathies | Age-Related Maculopathy | Retinal Neovascularization | Maculopathies, Age-Related | Maculopathy, Age-Related | Therapy, GeneUnited States
-
BiogenCompletedChoroideremiaUnited States, Finland, France, Denmark, Netherlands, Germany, United Kingdom, Canada
-
MeiraGTx UK II LtdSyne Qua Non Limited; Bionical EmasCompletedGene Therapy for X-linked Retinitis Pigmentosa (XLRP) - Retinitis Pigmentosa GTPase Regulator (RPGR)X-Linked Retinitis PigmentosaUnited Kingdom, United States